Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

About this update from Dianthus Therapeutics, Inc.

NEW YORK and WALTHAM, Mass. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia , Chief Executive Officer, at the following healthcare investor conferences during the month of September: Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York City Cantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York City Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 at 10:30 a.m. ET via Zoom Live webcasts of the Company’s presentations at the Cantor and Stifel conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website . About Dianthus Therapeutics Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass. , Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn . Contact Jennifer Davis Ruff Dianthus Therapeutics [email protected] Source: Dianthus Therapeutics, Inc.

View stock analysis, news, and events for Dianthus Therapeutics, Inc.